Full Press Release Details
THE SHARE REPURCHASE PROGRAM AUTHORISED BY THE ORDINARY GENERAL MEETING OF 19 MAY 2022
241-2 of the AMF General Regulations (R glement G n ral de l'Autorit des march s financiers),
the purpose of this description is to present the objectives and terms of the share repurchase program of Inventiva S.A. (the "Company")
as approved by the Ordinary General Meeting of May 19, 2022.
of the share repurchase program pursuant to the 19th resolution of the Ordinary General Meeting of May 19, 2022 are:
its discretion, may purchase shares pursuant to the program on one or more occasions and at the times it shall determine; there is no
assurance that the Company will exercise the authority to purchase shares to the maximum extent authorized, or at all.
clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of
NASH and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain
of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva's lead product candidate,
lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with NASH, a common and
progressive chronic liver disease for which there are currently no approved therapies.
established a strategic collaboration with AbbVie in the area of autoimmune diseases that resulted in the discovery of the drug candidate
cedirogant (ABBV-157), an oral ROR inverse agonist which is being evaluated in a Phase IIb clinical trial, led by AbbVie, in adult
patients with moderate to severe chronic plaque psoriasis. Inventiva's pipeline also includes odiparcil, a drug candidate for the
treatment of adult mucopolysaccharidoses (MPS) VI patients. As part of Inventiva's decision to focus clinical efforts on the development
of lanifibranor, it suspended clinical efforts relating to odiparcil and is reviewing available options with respect to its potential
further development. Inventiva is in the process of selecting an oncology development candidate for its Hippo signalling pathway program.
a scientific team of approximately 80 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules,
approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.
public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA - ISIN: FR0013233012) and on the Nasdaq
Global Market in the United States (ticker: IVA). www.inventivapharma.com.
release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are
forward-looking statements. These statements include, but are not limited to, forecasts and estimates with respect to
Inventiva's pipeline and preclinical and clinical development plans, future activities, expectations, plans,
growth and prospects of Inventiva and the sufficiency of Inventiva's cash resources and cash runway; and whether or to
what extent Inventiva may use the share repurchase program and the
objectives of any use of the share repurchase program. Certain of these statements, forecasts and estimates can be recognized by the
use of words such as, without limitation, "believes", "anticipates", "expects",
"intends", "plans", "seeks", "estimates", "may", "will",
"would", "could", "might", "should", and "continue" and similar
expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking
statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of
the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events
to differ materially from those expressed or implied in such statements. Future events are difficult to predict and may depend upon
factors that are beyond Inventiva's control. There can be no guarantees with respect to pipeline product candidates that the
clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as
anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by
Inventiva or its partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially
different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and
estimates, due to a number of factors, including that Inventiva is a clinical-stage company with no approved products and no
historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has a limited operating history
and has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations,
Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization
of current and any future product candidates, preclinical studies or earlier clinical trials are not necessarily predictive of
future results and the results of Inventiva's clinical trials may not support Inventiva's product candidate claims, Inventiva may
encounter substantial delays in its clinical trials or Inventiva may fail to demonstrate safety and efficacy to the satisfaction of
applicable regulatory authorities, enrollment and retention of patients in clinical trials is an expensive and time-consuming
process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's control, Inventiva's product
candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit
their commercial potential, Inventiva faces substantial competition and Inventiva's business, and preclinical studies and
clinical development programs and timelines, its financial condition and results of operations could be materially and adversely
affected by the current COVID-19 pandemic and geopolitical events, such as the conflict between Russia and Ukraine and related
impacts and potential impacts on the initiation, enrolment and completion of Inventiva's clinical trials on anticipated
timelines. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking
statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of
this press release. Readers are cautioned not to place undue reliance on any of these forward-looking
to the Universal Registration Document for the year ended December 31, 2021 filed with the Autorit des March s Financiers
on March 11, 2022 and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the Securities and Exchange Commission
on March 11, 2022 for additional information in relation to such factors, risks and uncertainties.
in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation
to update or review the forward-looking statements referred to above.